Opium (Opioid) Addiction – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Opium (Opioid) Addiction – Pipeline Review, H2 2017’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects

The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alkermes Plc

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Foresee Pharmaceuticals LLC

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opium (Opioid) Addiction - Overview

Opium (Opioid) Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opium (Opioid) Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opium (Opioid) Addiction - Companies Involved in Therapeutics Development

Alkermes Plc

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Foresee Pharmaceuticals LLC

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Opium (Opioid) Addiction - Drug Profiles

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANS-6637 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride depot - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canquit-O - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-4363467 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-5006739 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEV-90109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opioid Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opium Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opium (Opioid) Addiction - Dormant Projects

Opium (Opioid) Addiction - Discontinued Products

Opium (Opioid) Addiction - Product Development Milestones

Featured News & Press Releases

Sep 01, 2017: Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal

Aug 02, 2017: Zubsolv gains preferred position on CVS Caremark 2018 Formulary

Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

Jul 31, 2017: Indivior Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder

Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio

Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

Jul 10, 2017: Orexigen Announces Presentation of Data for OREX-1019, Candidate for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas

Jun 29, 2017: Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology

Jun 29, 2017: Indivior Provides Update on RBP-6000

Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms

Jun 21, 2017: Indivior Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine

Jun 13, 2017: Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE in Canada

Jun 06, 2017: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Opium (Opioid) Addiction – Pipeline by Alkermes Plc, H2 2017

Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by BioDelivery Sciences International Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Camurus AB, H2 2017

Opium (Opioid) Addiction – Pipeline by Fab'entech SA, H2 2017

Opium (Opioid) Addiction – Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Opium (Opioid) Addiction – Pipeline by Indivior Plc, H2 2017

Opium (Opioid) Addiction – Pipeline by Insys Therapeutics Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by iX Biopharma Ltd, H2 2017

Opium (Opioid) Addiction – Pipeline by Nemus Bioscience Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Novartis AG, H2 2017

Opium (Opioid) Addiction – Pipeline by Omeros Corp, H2 2017

Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Orexigen Therapeutics Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Orexo AB, H2 2017

Opium (Opioid) Addiction – Pipeline by Pfizer Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Relmada Therapeutics Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction – Dormant Projects, H2 2017

Opium (Opioid) Addiction – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports